Enquire Now

LEARN MORE Saliva based companion diagnostic test for Head & Neck Cancer Guiding Treatment, Guarding Lives

Homepage 15

SaliscopeTM - Transforming Head and Neck Cancer Treatment

Revolutionizing cancer detection—no blood, just breakthrough science. Our saliva-based, non-invasive assay empowers clinicians with clear, actionable insights for head and neck cancers.

Predict Therapeutic Response and Relapse Using Saliva-Based Diagnostics

  • First Head and Neck cancer test to be validated on Indian patients
  • Painless, saliva-based diagnostics replacing invasive procedures
  • Advanced laboratory diagnostics combining AI for precision and ease
  • Empowering global health with accurate, affordable, and scalable diagnostics
  • Real-time diagnostic and prognostic therapeutic assessment
  • Provides clinicians with actionable data to guide treatment and anticipate relapse risk

Why Genoscope?

Innovative Technology: Real-time cancer monitoring through a simple, saliva-based test.

Patient-Centric Approach: Non-invasive, painfree testing that puts comfort and convenience first.

High Accuracy: Lab-proven precision with 84.16% sensitivity, 96.25% specificity and 91% accuracy.

Our Science

Genoscope’s platform combines advanced molecular diagnostics with artificial intelligence to provide precise, non-invasive, and clinically actionable analytics for head and neck cancer, including prediction of treatment response, estimation of relapse risk, and comprehensive assessment of disease risk.

Step 1

Step 1

Non-invasive Saliva Sample Collection
Step 2

Step 2

RNA isolation from Extracellular Vesicles
Step 3

Step 3

Biomarker Quantification via qRT-PCR
Step 4

Step 4

AI-Based Risk Stratification and Prognostic Modelling

Research and Development


Our focus is on developing a well-researched, easy-to-use assay, rigorously tested across multiple centers to ensure accuracy and effectiveness.

Ethical and Regulatory Compliance


We initiate the process for DCGI clinical trials to validate our platform and move toward regulatory approval.

Community Engagement


We launch initiatives to educate the public and healthcare professionals about our technology.

Companion diagnostic test available at four time points

At the time of diagnosis

At the time of relapse

Before taking the first cycle of neoadjuvant chemo/immunotherapy

At the latest, following the first cycle of neoadjuvant chemo/immunotherapy.

Who Can Take This Test?

This test is designed to guide personalized treatment planning for head and neck cancer patients by predicting the most effective therapeutic options tailored to each individual’s condition. This test provides ongoing value during follow-up care by helping clinicians assess the likelihood of disease recurrence or the emergence of secondary malignancies, enabling timely interventions and improved patient management.

Genoscope is born from a deeply felt need in the oncology community – one rooted in real patient experiences. Nearly half of head and neck cancer patients encounter resistance to standard chemotherapeutic regimens. Even more concerning, only end-point treatment monitoring is possible for head and neck cancer patients.

530 +

Individuals successfully tested so far
Download Sample Report

Our Story

Genoscope is born from a deeply felt need in the oncology community — one rooted in real patient experiences. Nearly half of head and neck cancer patients encounter resistance to standard chemotherapeutic regimens. Even more concerning, only end-point treatment monitoring is possible for head and neck cancer patients. 

Can we predict treatment response before it even begins—using something as simple as saliva?

By combining innovation, science and a patient-centered approach, we have developed SaliscopeTM: an empowering tool for both patients and clinicians that enables informed decision-making without invasive procedures. Leveraging a panel of biomarkers, Saliscope offers precise patient stratification by predicting treatment response and relapse risk, thereby improving prognostic accuracy and facilitating tailored, more effective therapeutic strategies.

Our guiding principle: Why prick, when you can spit?

Meet the Minds Behind Genoscope

Genoscope is a collaboration of highly skilled professionals dedicated to advancing cancer diagnostics. Our team’s collective expertise and passion drives our mission forward.

Our Founders

Dr. Shanaya Patel

Founder and Director

With over 13 years of experience in cancer research, Dr. Patel’s vision for a less invasive cancer diagnostic tool led to the creation of Genoscope.

Dr. Kaustubh Patel

Co-Founder and Director

A distinguished surgical oncologist with 34 years of expertise in head and neck oncology, whose leadership drives our innovations in non-invasive cancer diagnostics.

Dr. Vivek Tanavde

Co-Founder and Director

Bringing 27 years of expertise in cancer diagnostics and research, he plays a pivotal role in shaping our innovation strategy and advancing R&D initiatives.

Dr. Dushyant Mandlik

Co-Founder and Clinical Expert

An expert in robotic and reconstructive head and neck surgery with 17 years of experience, he oversees clinical operations, ensuring both clinical credibility and effective project management.

Dr. Aditi Patel

Co-Founder and Chief Scientific Officer

Known for a fresh, research-driven approach, she advances scientific initiatives and delivers precise, high-impact solutions.

Our Team

Ms. Vaishnavi Patel

Project Assistant

Mr. Ashutosh Pardeshi

Algorithm Developer

Ms. Pranjali Bakeri

Algorithm Developer

Our team’s diverse experience and dedication form the core of Genoscope’s innovative approach to cancer care.

Contact Us

Get in Touch with Genoscope

We welcome your inquiries and are here to assist with any questions you may have about Genoscope.

    FAQs

    This test is prescribed to patients who have been diagnosed with cancer or are experiencing a recurrence. It is also recommended for patients who are prescribed chemotherapy or immunotherapy, as well as those seeking to assess their risk for secondary malignancies.

    The saliva sample can be easily collected either at our center or from the comfort of your home. After collection, the sample can be securely shipped to us on ice, ensuring it remains preserved and accurate for analysis.

    The test can only be taken at the time of diagnosis or upon recurrence, when chemotherapy is prescribed. Alternatively, it can be latest done after the first cycle of chemotherapy.

    PET-CT provides endpoint monitoring and can only predict outcomes after the completion of neo-adjuvant chemotherapy (NACT). Additionally, it does not assess the genetic risk of relapse or evaluate real-time therapy responses.

    This test does not replace existing diagnostics; rather, it serves as a companion assay, assisting clinicians in making more informed decisions.

    No, only in oral cancer with the sub-sites buccal mucosa, retromolar trigone, GB sulcus, tongue, palate.

    It takes around 36-48 hours.

    Publications and Patent

    Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?
    Patel, A., Patel, S., Patel, P., & Tanavde, V. (2022). Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?. Frontiers in oncology, 12, 828434. https://doi.org/10.3389/fonc.2022.828434

    A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma.
    Patel, A., Patel, P., Mandlik, D., Patel, K., Malaviya, P., Johar, K., Swamy, K. B. S., Patel, S., &Tanavde, V. (2023). A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma. Biomarker research, 11(1), 64. https://doi.org/10.1186/s40364-023-00505-5

    Salivary Exosomal miRNA-1307-5p Predicts Disease Aggressiveness and Poor Prognosis in Oral Squamous Cell Carcinoma Patients.
    Patel, A., Patel, S., Patel, P., Mandlik, D., Patel, K., &Tanavde, V. (2022). Salivary Exosomal miRNA-1307-5p Predicts Disease Aggressiveness and Poor Prognosis in Oral Squamous Cell Carcinoma Patients. International journal of molecular sciences, 23(18), 10639. https://doi.org/10.3390/ijms231810639

    Patent
    A kit for real-time therapeutic monitoring and relapse prediction of head and neck cancer patients (Application number: 202421066127, Dated: 23rd August, 2024)

    Our partners and enablers

    © 2025 Genoscope Pvt Ltd. All rights reserved.